Refer A Friend

Contact Us

Upcoming

GLP Switch

C6491015
This study is for patients currently on a stable dose of Wegovy (semaglutide) or Zepbound (tirzepatide). The study is evaluating the effectiveness of switching to a drug with monthly dosing to help lose or keep of the weight. 
Status: 
Upcoming
Compensation: 
Up to $1,612
Location: Greenville - 545 Verdae Blvd., Lower Level, Suite B
Number of Visits: 
Discussed at screening
Age Group: 
18+
Qualifications: 
Have taken Wegovy or Zepbound for at least 6 months and on the same dose for 3 months. Cannot be on a compounded medication. Experiencing a weight stability (plateau) for at least 6 weeks. BMI of 25 or greater.
Location(s):
Greenville - 545 Verdae Blvd., Lower Level, Suite B
*You may receive compensation for your time and completed study visits.

Other Popular Trials

Get in Touch
Phone: 864.334.0141
Fax: 864.334.0137
Join Our Email List
Stay informed about our clinical trials and 
community events.*
Sign Me Up
*By submitting this form, you agree to receive email 
notifications from us. You can unsubscribe at any time.
Follow Us:
©2026 Tribe Clinical Research
All Rights Reserved